This course has expired. View available courses.
Endocrinology
Moving forward towards better control: Reaching diabetes targets by reducing therapeutic inertia
Type 2 diabetes is a progressive condition in which intensification of therapy will be required to maintain glycemic control. Current Diabetes Canada clinical practice guidelines recommend adjustment and intensification of antihyperglycemic therapy to reach A1C targets within 3 to 6 months. Chart audits have shown that it is common for diabetes patients not to be offered changes in pharmacotherapy when their A1C is above target. The COVID-19 pandemic has likely worsened this situation. This program will provide clinicians with an approach to better address resistance to intensification and therapeutic inertia with practical recommendations that can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from IQVIA.
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
Mainpro+
EXPIRY DATE
2023-01-22
Type 2 diabetes is a progressive condition in which intensification of therapy will be required to maintain glycemic control. Current Diabetes Canada clinical practice guidelines recommend adjustment and intensification of antihyperglycemic therapy to reach A1C targets within 3 to 6 months. Chart audits have shown that it is common for diabetes patients not to be offered changes in pharmacotherapy when their A1C is above target. The COVID-19 pandemic has likely worsened this situation. This program will provide clinicians with an approach to better address resistance to intensification and therapeutic inertia with practical recommendations that can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from IQVIA.
Faculty
Maureen Clement, MD, CFPC
Jeffrey Habert, MD, CFPC, FCFP
Noah Ivers, MD, PhD, CFPC
James Kim, MBBCh, PgDip
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Define therapeutic inertia and its impact on people living with type 2 diabetes
- Review the role of patients, clinicians and the healthcare system in therapeutic inertia
- Determine strategies to reduce therapeutic inertia in practice
- Apply therapeutic inertia strategies to clinical cases
Accreditation
#
of credits: 1
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Physician
Profession
1
# of credits
Learning Objectives
Upon completion of this continuing education program participants will be better able to:
- Define therapeutic inertia and its impact on people living with type 2 diabetes
- Review the role of patients, clinicians and the healthcare system in therapeutic inertia
- Determine strategies to reduce therapeutic inertia in practice
- Apply therapeutic inertia strategies to clinical cases
Mainpro+
ACCREDITATION
Endocrinology
Learning Category
Diabetes
Topic
0
Price
2023-01-22
Expiry Date
CAN-eng
Region/Language
Course Description
Type 2 diabetes is a progressive condition in which intensification of therapy will be required to maintain glycemic control. Current Diabetes Canada clinical practice guidelines recommend adjustment and intensification of antihyperglycemic therapy to reach A1C targets within 3 to 6 months. Chart audits have shown that it is common for diabetes patients not to be offered changes in pharmacotherapy when their A1C is above target. The COVID-19 pandemic has likely worsened this situation. This program will provide clinicians with an approach to better address resistance to intensification and therapeutic inertia with practical recommendations that can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from IQVIA.
Faculty
Maureen Clement, MD, CFPC
Jeffrey Habert, MD, CFPC, FCFP
Noah Ivers, MD, PhD, CFPC
James Kim, MBBCh, PgDip
Accreditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits.
Cert+ Program ID#: 196260
1 hr
Duration
0
Price
1
# of credits
